QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer

February 22, 2023

Austin, TX, Feb. 22, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB:QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases and conditions, today announces the addition of the Ellis Fischel Cancer Center (EFCC) at the University of Missouri (MU) School of Medicine (SOM) as an upcoming clinical trial site to soon begin enrolling participants into the Phase 1 study evaluating CycloSam® for participants with multiple types of bone cancer that either originated in or has metastasized to the bone.

Read more at globenewswire.com

Related news for (QSAM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.